KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Non-Current Assets (2016 - 2025)

Rigel Pharmaceuticals has reported Non-Current Assets over the past 16 years, most recently at $273.4 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $273.4 million for Q4 2025, up 847.0% from a year ago — trailing twelve months through Dec 2025 was $361.8 million (up 179.28% YoY), and the annual figure for FY2025 was $273.4 million, up 847.0%.
  • Non-Current Assets for Q4 2025 was $273.4 million at Rigel Pharmaceuticals, up from $27.6 million in the prior quarter.
  • Over the last five years, Non-Current Assets for RIGL hit a ceiling of $273.4 million in Q4 2025 and a floor of $5.2 million in Q3 2022.
  • Median Non-Current Assets over the past 5 years was $18.8 million (2021), compared with a mean of $33.4 million.
  • Biggest five-year swings in Non-Current Assets: tumbled 66.47% in 2022 and later skyrocketed 847.0% in 2025.
  • Rigel Pharmaceuticals' Non-Current Assets stood at $12.9 million in 2021, then soared by 42.88% to $18.4 million in 2022, then fell by 2.27% to $18.0 million in 2023, then soared by 60.77% to $28.9 million in 2024, then skyrocketed by 847.0% to $273.4 million in 2025.
  • The last three reported values for Non-Current Assets were $273.4 million (Q4 2025), $27.6 million (Q3 2025), and $31.3 million (Q2 2025) per Business Quant data.